CymaBay Therapeutics
Biopharmaceutical company focused on discovery, development and delivery of therapies across virology, oncology and inflammation. Operates integrated R&D and clinical development pipelines (including cell-therapy development), maintains global medication access and patient support programs, manages pharmacovigilance and product safety, and executes manufacturing readiness and distribution planning to enable global access.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Therapeutic portfolios for virology, oncology and inflammation
Broad portfolio of approved and investigational therapeutics across antiviral, oncology and inflammatory disease modalities, including small molecules, biologics, ADCs and cell therapies.
Therapeutic portfolios for virology, oncology and inflammation
Broad portfolio of approved and investigational therapeutics across antiviral, oncology and inflammatory disease modalities, including small molecules, biologics, ADCs and cell therapies.
Services
Funding and support for externally sponsored research, investigator scholar awards and community-based participatory research projects.
Evaluation and provision processes for individual patient access to investigational medicines outside clinical trials, including case review workflows for cell therapy requests.
Digital platform listing clinical trials across therapeutic areas to support investigator and patient access to study information and enrollment.
Provision of clinical and scientific information resources for healthcare professionals.
Publication and management of authorized distributor lists and limited specialty pharmacy networks to support legitimate distribution and patient access.
Funding and support for externally sponsored research, investigator scholar awards and community-based participatory research projects.
Evaluation and provision processes for individual patient access to investigational medicines outside clinical trials, including case review workflows for cell therapy requests.
Digital platform listing clinical trials across therapeutic areas to support investigator and patient access to study information and enrollment.
Provision of clinical and scientific information resources for healthcare professionals.
Publication and management of authorized distributor lists and limited specialty pharmacy networks to support legitimate distribution and patient access.
Expertise Areas
- Clinical trial management and diversity-focused recruitment
- Oncology R&D and translational development (including ADCs and combination strategies)
- Cell therapy development and manufacturing (CAR T)
- Virology research and antiviral development
Key Technologies
- Cell therapy platforms (CAR T)
- Antibody-drug conjugates (ADC)
- Monoclonal and bispecific antibody therapeutics
- Therapeutic vaccine development
News & Updates
Announcement of manufacturing readiness and supply planning actions to enable access to an investigational once-yearly long-acting HIV prevention product, if approved.
Partnership announcement with a regional public health organization to expand access planning for a twice-yearly HIV prevention product.
Announcement of a new research center to support research and development activities.
U.S. FDA approval of a new once-daily single-tablet HIV treatment option.
Regulatory expansion of an oncology therapy's approved indication in first-line metastatic triple-negative breast cancer across PD-L1 status.
Announcement of planned investor presentations by the company.
Announcement of manufacturing readiness and supply planning actions to enable access to an investigational once-yearly long-acting HIV prevention product, if approved.
Partnership announcement with a regional public health organization to expand access planning for a twice-yearly HIV prevention product.
Announcement of a new research center to support research and development activities.
U.S. FDA approval of a new once-daily single-tablet HIV treatment option.
Regulatory expansion of an oncology therapy's approved indication in first-line metastatic triple-negative breast cancer across PD-L1 status.
Announcement of planned investor presentations by the company.